Dowbenko D, Nakamura G, Fennie C, Shimasaki C, Riddle L, Harris R, Gregory T, Lasky L
Department of Molecular Immunology, Genentech, Inc., South San Francisco, California 94080.
J Virol. 1988 Dec;62(12):4703-11. doi: 10.1128/JVI.62.12.4703-4711.1988.
A soluble form of recombinant gp120 of human immunodeficiency virus type 1 was used as an immunogen for production of murine monoclonal antibodies. These monoclonal antibodies were characterized for their ability to block the interaction between gp120 and the acquired immunodeficiency syndrome virus receptor, CD4. Three of the monoclonal antibodies were found to inhibit this interaction, whereas the other antibodies were found to be ineffective at blocking binding. The gp120 epitopes which are recognized by these monoclonal antibodies were mapped by using a combination of Western blot (immunoblot) analysis of gp120 proteolytic fragments, immunoaffinity purification of fragments of gp120, and antibody screening of a random gp120 gene fragment expression library produced in the lambda gt11 expression system. Two monoclonal antibodies which blocked gp120-CD4 interaction were found to map to adjacent sites in the carboxy-terminal region of the glycoprotein, suggesting that this area is important in the interaction between gp120 and CD4. One nonblocking antibody was found to map to a position that was C terminal to this CD4 blocking region. Interestingly, the other nonblocking monoclonal antibodies were found to map either to a highly conserved region in the central part of the gp120 polypeptide or to a highly conserved region near the N terminus of the glycoprotein. N-terminal deletion mutants of the soluble envelope glycoprotein which lack these highly conserved domains but maintain the C-terminal CD4 interaction sites were unable to bind tightly to the CD4 receptor. These results suggest that although the N-terminal and central conserved domains of intact gp120 do not appear to be directly required for CD4 binding, they may contain information that allows other parts of the molecule to form the appropriate structure for CD4 interaction.
人免疫缺陷病毒1型重组gp120的可溶性形式被用作免疫原,用于生产鼠单克隆抗体。对这些单克隆抗体阻断gp120与获得性免疫缺陷综合征病毒受体CD4之间相互作用的能力进行了表征。发现其中三种单克隆抗体可抑制这种相互作用,而其他抗体在阻断结合方面无效。通过对gp120蛋白水解片段进行蛋白质印迹(免疫印迹)分析、对gp120片段进行免疫亲和纯化以及对在λgt11表达系统中产生的随机gp120基因片段表达文库进行抗体筛选,确定了这些单克隆抗体识别的gp120表位。发现两种阻断gp120-CD4相互作用的单克隆抗体定位于糖蛋白羧基末端区域的相邻位点,表明该区域在gp120与CD4的相互作用中很重要。发现一种非阻断抗体定位于该CD4阻断区域C末端的位置。有趣的是,发现其他非阻断单克隆抗体要么定位于gp120多肽中部的高度保守区域,要么定位于糖蛋白N末端附近的高度保守区域。缺乏这些高度保守结构域但保留C末端CD4相互作用位点的可溶性包膜糖蛋白的N末端缺失突变体无法与CD4受体紧密结合。这些结果表明,虽然完整gp120的N末端和中部保守结构域似乎不是CD4结合直接必需的,但它们可能包含使分子其他部分形成与CD4相互作用的适当结构的信息。